UBS Group Increases AnaptysBio (NASDAQ:ANAB) Price Target to $33.00

AnaptysBio (NASDAQ:ANAB - Free Report) had its price objective upped by UBS Group from $23.00 to $33.00 in a report published on Wednesday morning, Benzinga reports. They currently have a neutral rating on the biotechnology company's stock.

ANAB has been the subject of a number of other reports. HC Wainwright reiterated a "buy" rating and issued a $55.00 price target on shares of AnaptysBio in a report on Wednesday, August 14th. Truist Financial increased their target price on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a "hold" rating in a report on Thursday, August 15th. Guggenheim boosted their price objective on shares of AnaptysBio from $75.00 to $90.00 and gave the company a "buy" rating in a research report on Monday, October 21st. Wedbush restated an "outperform" rating and set a $42.00 price objective on shares of AnaptysBio in a research note on Thursday, September 26th. Finally, JPMorgan Chase & Co. boosted their price target on shares of AnaptysBio from $69.00 to $75.00 and gave the company an "overweight" rating in a report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $55.73.

AnaptysBio Trading Down 28.0 %

ANAB stock traded down $8.62 during midday trading on Wednesday, hitting $22.18. 3,235,216 shares of the company's stock were exchanged, compared to its average volume of 340,180. The stock has a market capitalization of $605.94 million, a price-to-earnings ratio of -4.04 and a beta of -0.29. The firm has a 50 day moving average price of $35.23 and a 200-day moving average price of $29.93. AnaptysBio has a 12-month low of $13.36 and a 12-month high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.82). The company had revenue of $10.97 million for the quarter, compared to analyst estimates of $25.85 million. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. On average, sell-side analysts forecast that AnaptysBio will post -6.84 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Dennis Mulroy sold 12,220 shares of the firm's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the transaction, the chief financial officer now owns 4,744 shares in the company, valued at approximately $189,333.04. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, insider Paul F. Lizzul sold 1,500 shares of the company's stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the sale, the insider now directly owns 15,398 shares of the company's stock, valued at $595,440.66. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Dennis Mulroy sold 12,220 shares of the business's stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $39.91, for a total value of $487,700.20. Following the sale, the chief financial officer now owns 4,744 shares in the company, valued at approximately $189,333.04. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,440 shares of company stock valued at $892,936 over the last three months. Company insiders own 33.70% of the company's stock.

Hedge Funds Weigh In On AnaptysBio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers boosted its position in shares of AnaptysBio by 1.8% in the second quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company's stock worth $745,000 after buying an additional 525 shares during the period. Algert Global LLC increased its stake in AnaptysBio by 11.8% in the 2nd quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company's stock valued at $255,000 after buying an additional 1,078 shares during the period. nVerses Capital LLC boosted its stake in shares of AnaptysBio by 700.0% during the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company's stock valued at $54,000 after buying an additional 1,400 shares during the period. Values First Advisors Inc. purchased a new position in shares of AnaptysBio during the 3rd quarter valued at $49,000. Finally, Allspring Global Investments Holdings LLC acquired a new position in shares of AnaptysBio in the first quarter worth $38,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.